These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36239939)

  • 1. Participation of Older Adults in Clinical Trials for New Drug Applications and Biologics License Applications From 2010 Through 2019.
    Lau SWJ; Huang Y; Hsieh J; Wang S; Liu Q; Slattum PW; Schwartz JB; Huang SM; Temple R
    JAMA Netw Open; 2022 Oct; 5(10):e2236149. PubMed ID: 36239939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
    Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
    Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.
    Poon R; Khanijow K; Umarjee S; Fadiran E; Yu M; Zhang L; Parekh A
    J Womens Health (Larchmt); 2013 Jul; 22(7):604-16. PubMed ID: 23768021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demographic Disparities in the Federal Drug Approval Process for Allergic Rhinitis Medications.
    Liebowitz A; Spielman DB; Schlosser RJ; Stewart MG; Gudis DA
    Laryngoscope; 2023 Apr; 133(4):755-763. PubMed ID: 35394648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
    Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
    JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015.
    Chen A; Wright H; Itana H; Elahi M; Igun A; Soon G; Pariser AR; Fadiran EO
    J Womens Health (Larchmt); 2018 Apr; 27(4):418-429. PubMed ID: 29048983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inclusion of Older People Reflective of Real-World Clinical Practice in Cardiovascular Drug Trials.
    Caughey GE; Inacio MC; Bell JS; Vitry AI; Shakib S
    J Am Heart Assoc; 2020 Nov; 9(21):e016936. PubMed ID: 33103558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018.
    Heyward J; Moore TJ; Chen J; Meek K; Lurie P; Alexander GC
    Ann Intern Med; 2020 Dec; 173(12):956-963. PubMed ID: 32986486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs.
    Scott PE; Unger EF; Jenkins MR; Southworth MR; McDowell TY; Geller RJ; Elahi M; Temple RJ; Woodcock J
    J Am Coll Cardiol; 2018 May; 71(18):1960-1969. PubMed ID: 29724348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Clinical Characteristics and Treatment Patterns of Individuals Aged 80 and Older with Nonvalvular Atrial Fibrillation: Results from the ReAl-life Multicenter Survey Evaluating Stroke Study.
    Biteker M; Başaran Ö; Doğan V; Altun İ; Özpamuk Karadeniz F; Tekkesin Aİ; Çakıllı Y; Türkkan C; Hamidi M; Demir V; Gürsoy MO; Tek Öztürk M; Aksan G; Seyis S; Ballı M; Alıcı MH; Bozyel S
    J Am Geriatr Soc; 2017 Aug; 65(8):1684-1690. PubMed ID: 28394435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of Incident and Recurrent Major Depression in Older Adults With Insomnia: A Randomized Clinical Trial.
    Irwin MR; Carrillo C; Sadeghi N; Bjurstrom MF; Breen EC; Olmstead R
    JAMA Psychiatry; 2022 Jan; 79(1):33-41. PubMed ID: 34817561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    Brunetti L; Chen C; White J
    Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Real-World Evidence in Neuroscience-Related New Drug and Biologics License Applications for Novel Therapeutics.
    Bloomfield-Clagett B; Rahman M; Smith K; Concato J
    Clin Pharmacol Ther; 2023 Nov; 114(5):1002-1005. PubMed ID: 37548904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
    Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
    JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.
    Cope S; Clemens A; Hammès F; Noack H; Jansen JP
    Value Health; 2015 Mar; 18(2):234-49. PubMed ID: 25773559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Participation of Women and Older Participants in Randomized Clinical Trials of Lipid-Lowering Therapies: A Systematic Review.
    Khan SU; Khan MZ; Raghu Subramanian C; Riaz H; Khan MU; Lone AN; Khan MS; Benson EM; Alkhouli M; Blaha MJ; Blumenthal RS; Gulati M; Michos ED
    JAMA Netw Open; 2020 May; 3(5):e205202. PubMed ID: 32437574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the approved Risk Evaluation and Mitigation Strategy programs for New Drug Applications and Biologics Licensing Applications.
    Johnson NA; Priefer R
    Regul Toxicol Pharmacol; 2019 Feb; 101():53-56. PubMed ID: 30473489
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.